JMT Cochrane, Board member Wellcome and Glaxo; Director of Commercial Affairs for Europe

Interviewee joined the company in 1990, with the remit to "bring it into the 20th century".

The interview comprises a close assessment of the company, of its relationship with WT, the flotation and the merger with Glaxo. Other topics discussed include:

* biography

* differences between UK and US company

* reasons for flotation and preparations for sale of second lot of shares

* the effects of public accountability on the company, budgeting

* AJ Shepperd as chairman

* restructuring of the business, focus of research, commercial interests

* Semprex

* principles behind marketing drugs, establishing where markets are available, pricing

* salaries and staffing

* research: David Barry and Trevor Jones; relationship between UK and USA research functions

* management of research and product development: Zantac [Glaxo product]

* Wellbutrin

* strategic review of company

* markets in Germany and Japan

* relationship between company and WT

* Glaxo's approach to WT and reasons for wishin to takeover WF; process of selecting staff post-merger

* summary of Glaxo

* WF as an employeer/staff morale and attitudes

* John Robb, management and leadership style

17 Aug 2001

2 audio tapes and transcript Tape 35

This item needs to be accessed onsite using specialist equipment. Email collections@wellcomecollection.org to request an appointment.